Alimera Sciences

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Alimera Sciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 4 completed later-stage tilt upper quartile by trial count

Alimera Sciences: 8 sponsored US clinical trials, none currently recruiting.

Alimera Sciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Uveitis, Posterior, with 1 trials.

Upper-quartile sponsor footprint

Alimera Sciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 4

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
ACTIVE NOT RECRUITING Phase 4

A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

NCT04469595
COMPLETED Phase 4

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
COMPLETED Phase 3

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

NCT01304706
TERMINATED Phase 2

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
TERMINATED Phase 2

Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy

NCT00695318
COMPLETED Phase 3

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

NCT00344968
COMPLETED Phase 3

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 3
Phase 4 3

Therapeutic Areas

Uveitis, Posterior 1
Diabetic Macular Edema 1

How the Alimera Sciences archive is shaped

8 indexed studies, none listed as recruiting (0% open); 4 completed (50%).

Phase mix: 6 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Uveitis, Posterior (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Alimera Sciences: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Alimera SciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alimera Sciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Alimera Sciences page

8 registered trials is a research-attention snapshot, not an endorsement of Alimera Sciences or any single study.

  • None of Alimera Sciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Uveitis, Posterior is the condition Alimera Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Uveitis, Posterior trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alimera Sciences pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.